Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

Kiniksa Pharmaceuticals reports robust Q2 growth and strategic initiatives

Kiniksa Pharmaceuticals delivered a strong Q2 performance with significant revenue growth driven by ARCALYST sales and strategic initiatives. The company's focus on disease awareness and patient base expansion bodes well for future growth.
While challenges such as managing expenses and addressing operational complexities persist, Kiniksa's solid financial position and market opportunities position it favorably for sustained growth and value creation.
Overall, Kiniksa Pharmaceuticals' Q2 earnings call highlights a mix of strong performance, strategic strengths, operational challenges, and growth opportunities, signaling a dynamic and evolving landscape for the company.

Kiniksa Pharmaceuticals reports robust earnings, eyes growth through key programs

Kiniksa Pharmaceuticals delivered strong financial results in Q4 2024, driven by robust revenue growth and collaboration profits, positioning the company for continued success. While facing challenges such as portfolio diversification and upcoming trials, Kiniksa Pharmaceuticals has opportunities to leverage key programs for growth and market expansion. With a solid financial foundation, ownership of key programs, and strategic focus, Kiniksa Pharmaceuticals is poised for sustained growth and innovation in the biopharmaceutical industry.

Kiniksa Pharmaceuticals excels in Q1 earnings, eyes clinical trial milestones

Kiniksa Pharmaceuticals demonstrated strong financial performance in Q1 2025, marked by revenue growth, improved profitability, and successful collaborations. While facing challenges in pricing optimization and operational execution, the company's strategic strengths in cash reserves, product guidance, and customer-centric approach position it well for future growth. By capitalizing on upcoming clinical trials and market expansion opportunities, Kiniksa can leverage its current momentum to drive innovation, revenue diversification, and sustainable success.

Kiniksa Pharmaceuticals reports strong Q2 performance and growth opportunities

Kiniksa Pharmaceuticals demonstrated robust financial performance and strategic focus in Q2 2025, driven by ARCALYST's revenue growth and market impact. While facing challenges in competitive dynamics and regulatory scrutiny, the company's strong balance sheet and product acceptance position it well for future growth. Opportunities lie in leveraging ARCALYST's success, advancing pipeline development, and exploring new growth avenues through strategic initiatives and market expansion.

Kiniksa Pharmaceuticals reports robust Q3 earnings, eyes market expansion

Kiniksa Pharmaceuticals demonstrated strong financial performance in Q3 driven by ARCALYST's success in treating recurrent pericarditis. The company's focus on IL-1 immunomodulation and potential of KPL-387 position it well for future growth. Challenges in competition and strategic decision-making require attention for sustained success.

Kiniksa Pharmaceuticals reports record revenue growth and eyes market expansion

Kiniksa Pharmaceuticals delivered strong financial performance in Q4 2025, driven by robust ARCALYST revenue growth. The company's strategic investments in R&D and plans for ARCALYST expansion signal a positive outlook for future revenue. While facing challenges in market penetration and FDA interactions, Kiniksa Pharmaceuticals has opportunities for growth and market expansion.

Kiniksa Pharmaceuticals reports robust Q1 earnings and optimistic growth outlook

Kiniksa Pharmaceuticals delivered strong financial performance in Q1 2026, with notable revenue and net income growth. The company's strategic focus on new prescribers, patient enrollments, and innovative campaigns like 'Heart's Home' has positioned it well for future success. Addressing challenges around campaign impact, co-payment dynamics, and R&D expenses will be crucial for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.